Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01817270
Other study ID # NCT02038506
Secondary ID
Status Completed
Phase Phase 4
First received March 4, 2013
Last updated October 14, 2013
Start date March 2013
Est. completion date August 2013

Study information

Verified date October 2013
Source Changchun Keygen Biological Products Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.


Recruitment information / eligibility

Status Completed
Enrollment 368
Est. completion date August 2013
Est. primary completion date August 2013
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Year to 3 Years
Eligibility Inclusion Criteria:

- Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent

- Participant is aged = 1 year to = 3 years

- Participant without preventive inoculation of varicella vaccine and previous history of chickenpox and zoster

- Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures

- Body temperature = 37.5?

Exclusion Criteria:

- Known allergy to any constituent of the vaccine

- Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever

- Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth

- Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction

- Failed to the Expanded Programme on Immunization(EPI)

- Receipt of any vaccine in the 4 weeks preceding the trial vaccination

- Plan to receive any vaccine in the 4 weeks following the trial vaccination

- Known bleeding disorder

- Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the trial vaccination

- Reported the history of acute illness had need systemic antibiotics or anti-viral treatment of infections in the 7 days preceding the trial vaccination

- An acute illness with or without fever (temperature = 38.0?) in the 3 days preceding enrollment in the trial

- Participation in any other interventional clinical trial

- Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Live Attenuated Varicella Vaccine


Locations

Country Name City State
China Xinxing Center for Disease Control and Prevention Yunfu Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Changchun Keygen Biological Products Co., Ltd. Guangdong Provincial Institute of Biological Products And Materia Medica

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seroconversion rate and GMTs for live attenuated varicella vaccine 35-42 days after the first and second doses
Secondary Occurrence of adverse events within 30 days after each vaccination
See also
  Status Clinical Trial Phase
Completed NCT01887496 - Varicella-related Hospitalizations in Turkey N/A
Completed NCT02570126 - A Safety and Immune Study of 2 Types of GlaxoSmithKline's Varicella Vaccines Given as a 2-doses Course to Healthy Children 12-23 Months of Age. Phase 3
Completed NCT00326183 - Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) Phase 4
Completed NCT02452229 - Review of Human Herpes Viruses in Burns N/A
Completed NCT01815073 - Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine Phase 4
Active, not recruiting NCT01982409 - Immune Persistence After Inoculated With One-dose Freeze-Dried Live Attenuated Varicella Vaccine in Children Vaccine in Children Phase 4
Completed NCT00921999 - Immune Response to Varicella-Zoster Vaccination and Infection N/A
Completed NCT00098046 - Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection Phase 3
Completed NCT05732337 - Open Clinical Investigation to Evaluate the Effectiveness and Safety of a Topical Medical Device. N/A
Completed NCT01684072 - Safety and Immunogenicity Study of Live Attenuated Vaccine Against Varicella Without Gelatin Phase 4
Completed NCT00156559 - MMR and Varicella Vaccine in Premature Infants Phase 4
Active, not recruiting NCT05084508 - A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age Phase 2
Completed NCT04384016 - Safety and Immunogenicity of Skyvaricella Injection in Healthy Volunteer Vietnamese Children From 12 Months to 12 Years Old Phase 4
Withdrawn NCT00001054 - The Safety and Effectiveness of Valacyclovir HCl in the Treatment of Herpes Simplex or Varicella/Zoster Infections in HIV-1 Infected Children Phase 1
Completed NCT00000953 - Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients Phase 2
Completed NCT00002358 - A Study of BV-araU in the Treatment of Varicella-Zoster Viral Disease (VZV) in HIV-Infected Children Who Have Not Had Success With or Who Cannot Take Other Treatments for VZV Phase 3
Completed NCT00002315 - A Comparison of 882C87 Versus Acyclovir in the Treatment of Herpes Zoster in Patients With Weakened Immune Systems Phase 3
Completed NCT00001125 - Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox Phase 1